Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03474497
Title Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of California, Davis
Indications

head and neck squamous cell carcinoma

renal cell carcinoma

lung non-small cell carcinoma

melanoma

Therapies

Aldesleukin + Pembrolizumab + Radiotherapy

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
UC Davis Medical Center Sacramento California 95817 United States Details
University of California Davis Medical Center Sacramento California 97817 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field